3320.HK Stock — Price, Charts & Analysis

China Resources Pharmaceutical Group Limited (3320.HK) has a trailing P/E of 6.50x and a forward P/E of 5.68x. This places 3320.HK in a lower earnings multiple territory based on the valuation data currently available on Worldtickers.

3320.HK trades with 6.50x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether 3320.HK looks overvalued or undervalued.

3320.HK's P/E of 6.50x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

3320.HK's trailing EPS is HK$0.74 and forward EPS is HK$0.85. Reported earnings growth is 171.00%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit China Resources Pharmaceutical Group Limited generated for each share. 3320.HK's trailing EPS is HK$0.74, and investors usually prefer EPS that is positive and growing over time.

China Resources Pharmaceutical Group Limited has a market cap of HK$30.22B, making 3320.HK a large-cap stock based on the current market value shown on Worldtickers.

3320.HK's latest stock price on Worldtickers is HK$4.81. The latest move is -HK$0.08 or -1.54%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

3320.HK's quote includes a latest price of HK$4.81. The market open is HK$4.93. Previous close is HK$4.89. The intraday range is HK$4.76 to HK$4.93.

3320.HK is down in the latest quote, with a move of -HK$0.08 or -1.54%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

3320.HK generated HK$269.57B in trailing revenue. Revenue growth is 6.70%, which helps show whether demand is expanding or slowing.

3320.HK's revenue growth is 6.70%, which is a positive demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, 3320.HK shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is HK$4.04B.

Gross margin is 16.51%. Margins show how efficiently China Resources Pharmaceutical Group Limited turns revenue into profit.

China Resources Pharmaceutical Group Limited carries HK$72.77B and holds HK$27.91B in cash.

3320.HK holds HK$27.91B on its balance sheet.

3320.HK's book value per share is HK$9.53.

Yes, China Resources Pharmaceutical Group Limited pays a dividend of HK$0.22 per share annually. The dividend yield is 446.00%. The payout ratio is 19.32%.

3320.HK's dividend yield is 446.00%. Its payout ratio is 19.32%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for 3320.HK. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through China Resources Pharmaceutical Group Limited's investor relations materials.

3320.HK's five-year average dividend yield is 325.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 5.52% of 3320.HK shares. Insiders hold 70.83% of shares. Ownership mix helps investors understand how much of China Resources Pharmaceutical Group Limited is held by professional investors and company insiders.

3320.HK has 6.28B shares outstanding. Float shares are 1.83B. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for 3320.HK, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for 3320.HK is HK$0.85. Earnings growth is 171.00%. Revenue growth is 6.70%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

3320.HK's trailing EPS is HK$0.74. Forward EPS is HK$0.85. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

3320.HK is in the Healthcare sector. Its earnings multiple is 6.50x. Its latest displayed growth metric is 6.70%. Compare these figures with sector peers before deciding whether China Resources Pharmaceutical Group Limited is stronger or weaker than average.

3320.HK trades at HK$4.81. The stock trades at 6.50x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of China Resources Pharmaceutical Group Limited's fundamentals.

3320.HK risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is -0.39, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

3320.HK should be compared with companies in Drug Manufacturers - Specialty & Generic. Its earnings multiple is 6.50x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

China Resources Pharmaceutical Group Limited (3320.HK) operates in Healthcare, specifically Drug Manufacturers - Specialty & Generic. China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including

3320.HK trades on HKSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

3320.HK stock is priced in HKD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

China Resources Pharmaceutical Group Limited's official website listed on Worldtickers is www.crpharm.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

China Resources Pharmaceutical Group Limited employs about 85.6K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

China Resources Pharmaceutical Group Limited is headquartered in Wan Chai, Hong Kong. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

3320.HK is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

3320.HK has traded between HK$4.22 and HK$6.53 over the past 52 weeks. At HK$4.81, it is 26.34% below the high and 13.98% above the low. The 52-week range helps gauge long-term price momentum.

3320.HK is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is HK$4.68 and its 200-day moving average is HK$4.74.

3320.HK's RSI is 56.38. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

3320.HK's latest RSI reading is 56.38, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for 3320.HK is near HK$4.72. Key resistance is near HK$4.95. Breaks above resistance or below support can change the short-term technical setup.

3320.HK's nearest reported support level is HK$4.72. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

3320.HK's nearest reported resistance level is HK$4.95. A breakout above resistance can improve momentum, especially when volume confirms the move.

3320.HK trades about 8.43M shares daily on average. The latest displayed volume is 8.24M shares. Volume helps show liquidity and whether trading interest is unusually high or low.

3320.HK's MACD is -0.01, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

3320.HK is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 56.38 (neutral). MACD is bearish. Nearest support is around HK$4.72. Resistance is around HK$4.95. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is HK$4.85 (0.62% from price). MA50 is HK$4.68 (4.33% from price). MA200 is HK$4.74 (3.16% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. 3320.HK's MA20 is HK$4.85. MA50 is HK$4.68. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

3320.HK's pivot is near HK$4.88. Support is near HK$4.72. Resistance is near HK$4.95. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for 3320.HK is near HK$4.72. The next upper resistance zone is near HK$5.11. These levels help define risk and possible follow-through zones after a breakout or breakdown.

3320.HK's Bollinger range is roughly HK$4.78 to HK$4.93. Band width is near 3.29%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

3320.HK's ATR-based typical daily range is about 2.36%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 8.24M shares. Average volume is about 8.43M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

3320.HK's all-time high shown on Worldtickers is HK$13.16. Its all-time low is HK$3.18. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

3320.HK has a beta of -0.39, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.